Cellular Immuno-Oncology 4.0

CELL AND GENE THERAPY INSIGHTS

May 2019

Cellular Immuno-Oncology 4.0

Download PDF

Editorial

The immunosuppressive tumor microenvironment: more than just immune checkpoints

The immunosuppressive tumor microenvironment: more than just immune checkpoints

Expert Insight

CAR T cell therapies in pediatric oncology: access and future development by distributed academic cell manufacturing

CAR T cell therapies in pediatric oncology: access and future development by distributed academic cell manufacturing

Claudia Rössig

Natural killer cells may be scaled and engineered as a next generation, off-the-shelf cell therapy for cancer

Natural killer cells may be scaled and engineered as a next generation, off-the-shelf cell therapy for cancer

Current state of genetically engineered macrophages for anti-cancer therapy

Current state of genetically engineered macrophages for anti-cancer therapy

N AP Lieberman, S Kreuser, C Lopez et al.

Gene editing platforms for T-cell immunotherapy

Gene editing platforms for T-cell immunotherapy

Xiuyan Wang, Isabelle Rivière

Genetically modified natural killer cells: an ‘off-the-shelf’ immunotherapy for cancer

Genetically modified natural killer cells: an ‘off-the-shelf’ immunotherapy for cancer

Subhashis Sarkar, Cillian O’Ceallaigh, Michael O’Dwyer

Perspective

How biomarkers can be used to optimize the clinical development of dendritic cell vaccines in immuno-oncology

How biomarkers can be used to optimize the clinical development of dendritic cell vaccines in immuno-oncology

The advantage of allogenicity when using Inflammatory dendritic cells as antitumor immune primers

The advantage of allogenicity when using Inflammatory dendritic cells as antitumor immune primers

S Longhurst, J Kovacka, E Heimann et al.

Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?

Immunotherapy with iPSC-derived dendritic cells brings a new perspective to an old debate: autologous versus allogeneic?

P J Fairchild, T Davies, C Horton et al.

Innovator Insight

Novel equipment and process changes: implications for your manufacturing strategy

Novel equipment and process changes: implications for your manufacturing strategy

Interview

Invariant NKT cells: progress in transitioning to the clinic

Invariant NKT cells: progress in transitioning to the clinic

Anastasios Karadimitris

Building robustness and scalability into the immuno-oncology supply chain

Building robustness and scalability into the immuno-oncology supply chain

Leading the charge: driving allogeneic CAR T cell immunotherapy towards clinical and commercial success

Leading the charge: driving allogeneic CAR T cell immunotherapy towards clinical and commercial success

Taking on solid tumors with genetically engineered macrophages

Taking on solid tumors with genetically engineered macrophages

Steven Kelly, Michael Klichinsky

The promise of tumor-targeted gene-based delivery of immune-activating cytokines

The promise of tumor-targeted gene-based delivery of immune-activating cytokines

γδT cells and the future of drug resistant immunotherapy

γδT cells and the future of drug resistant immunotherapy

Expert Roundtable Video

Expert Roundtable on immuno-oncology manufacturing: progress towards streamlined commercialization

Expert Roundtable on immuno-oncology manufacturing: progress towards streamlined commercialization

A Davies, Ø Åmellem, K Niss et al.

Expert Roundtable

Immuno-oncology manufacturing: progress towards streamlined commercialization

Immuno-oncology manufacturing: progress towards streamlined commercialization

A Davies, Ø Åmellem, K Niss et al.

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

S Kassim, J Krishnamurthy, T Laskowski et al.

Webinars

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

Gaining critical characterization insights for development of CAR-T therapies for solid tumors

T Laskowski, J O’Rourke, J Krishnamurthy

The power of ultra-high content and 3D imaging for the identification and characterisation of new CAR-T cell targets

The power of ultra-high content and 3D imaging for the identification and characterisation of new CAR-T cell targets

Olaf Hardt, Uwe Schröer